Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Replication competence of virions induced from CD4+ lymphocytes latently infected with HIV.

Richman DD, Huang K, Lada SM, Sun X, Jain S, Massanella M, Menke B.

Retrovirology. 2019 Feb 15;16(1):4. doi: 10.1186/s12977-019-0466-1.

2.

Improved assays to measure and characterize the inducible HIV reservoir.

Massanella M, Yek C, Lada SM, Nakazawa M, Shefa N, Huang K, Richman DD.

EBioMedicine. 2018 Oct;36:113-121. doi: 10.1016/j.ebiom.2018.09.036. Epub 2018 Oct 11.

3.

Quantitation of Integrated HIV Provirus by Pulsed-Field Gel Electrophoresis and Droplet Digital PCR.

Lada SM, Huang K, VanBelzen DJ, Montaner LJ, O'Doherty U, Richman DD.

J Clin Microbiol. 2018 Nov 27;56(12). pii: e01158-18. doi: 10.1128/JCM.01158-18. Print 2018 Dec.

4.

Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV.

Papasavvas E, Lada SM, Joseph J, Yin X, Liu Q, Azzoni L, Mounzer K, Kostman JR, Richman D, Montaner LJ.

AIDS. 2018 Aug 24;32(13):1763-1772. doi: 10.1097/QAD.0000000000001909.

5.

Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment.

White CH, Beliakova-Bethell N, Lada SM, Breen MS, Hurst TP, Spina CA, Richman DD, Frater J, Magiorkinis G, Woelk CH.

Front Immunol. 2018 Apr 12;9:603. doi: 10.3389/fimmu.2018.00603. eCollection 2018.

6.

Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study.

Cummins NW, Rizza S, Litzow MR, Hua S, Lee GQ, Einkauf K, Chun TW, Rhame F, Baker JV, Busch MP, Chomont N, Dean PG, Fromentin R, Haase AT, Hampton D, Keating SM, Lada SM, Lee TH, Natesampillai S, Richman DD, Schacker TW, Wietgrefe S, Yu XG, Yao JD, Zeuli J, Lichterfeld M, Badley AD.

PLoS Med. 2017 Nov 28;14(11):e1002461. doi: 10.1371/journal.pmed.1002461. eCollection 2017 Nov.

7.

Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.

Chaillon A, Gianella S, Lada SM, Perez-Santiago J, Jordan P, Ignacio C, Karris M, Richman DD, Mehta SR, Little SJ, Wertheim JO, Smith DM.

J Virol. 2018 Jan 17;92(3). pii: e01589-17. doi: 10.1128/JVI.01589-17. Print 2018 Feb 1.

8.

Effect of cytomegalovirus and Epstein-Barr virus replication on intestinal mucosal gene expression and microbiome composition of HIV-infected and uninfected individuals.

Gianella S, Chaillon A, Mutlu EA, Engen PA, Voigt RM, Keshavarzian A, Losurdo J, Chakradeo P, Lada SM, Nakazawa M, Landay AL.

AIDS. 2017 Sep 24;31(15):2059-2067. doi: 10.1097/QAD.0000000000001579. Erratum in: AIDS. 2018 Aug 24;32(13):1911.

9.

HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy.

Honeycutt JB, Thayer WO, Baker CE, Ribeiro RM, Lada SM, Cao Y, Cleary RA, Hudgens MG, Richman DD, Garcia JV.

Nat Med. 2017 May;23(5):638-643. doi: 10.1038/nm.4319. Epub 2017 Apr 17.

10.

Defective proviruses rapidly accumulate during acute HIV-1 infection.

Bruner KM, Murray AJ, Pollack RA, Soliman MG, Laskey SB, Capoferri AA, Lai J, Strain MC, Lada SM, Hoh R, Ho YC, Richman DD, Deeks SG, Siliciano JD, Siliciano RF.

Nat Med. 2016 Sep;22(9):1043-9. doi: 10.1038/nm.4156. Epub 2016 Aug 8.

11.

Replication of Human Herpesviruses Is Associated with Higher HIV DNA Levels during Antiretroviral Therapy Started at Early Phases of HIV Infection.

Gianella S, Anderson CM, Var SR, Oliveira MF, Lada SM, Vargas MV, Massanella M, Little SJ, Richman DD, Strain MC, Pérez-Santiago J, Smith DM.

J Virol. 2016 Mar 28;90(8):3944-3952. doi: 10.1128/JVI.02638-15. Print 2016 Apr.

12.

Quantification of Total and 2-LTR (Long terminal repeat) HIV DNA, HIV RNA and Herpesvirus DNA in PBMCs.

Massanella M, Gianella S, Lada SM, Richman DD, Strain MC.

Bio Protoc. 2015 Jun 5;5(11). pii: e1492.

13.

Select host restriction factors are associated with HIV persistence during antiretroviral therapy.

Abdel-Mohsen M, Wang C, Strain MC, Lada SM, Deng X, Cockerham LR, Pilcher CD, Hecht FM, Liegler T, Richman DD, Deeks SG, Pillai SK.

AIDS. 2015 Feb 20;29(4):411-20. doi: 10.1097/QAD.0000000000000572.

14.

Decreased HIV type 1 transcription in CCR5-Δ32 heterozygotes during suppressive antiretroviral therapy.

Wang C, Abdel-Mohsen M, Strain MC, Lada SM, Yukl S, Cockerham LR, Pilcher CD, Hecht FM, Sinclair E, Liegler T, Richman DD, Deeks SG, Pillai SK.

J Infect Dis. 2014 Dec 1;210(11):1838-43. doi: 10.1093/infdis/jiu338. Epub 2014 Jun 16.

15.

Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment.

Gianella S, Massanella M, Richman DD, Little SJ, Spina CA, Vargas MV, Lada SM, Daar ES, Dube MP, Haubrich RH, Morris SR, Smith DM; California Collaborative Treatment Group 592 Team.

J Virol. 2014 Jul;88(14):7818-27. doi: 10.1128/JVI.00831-14. Epub 2014 Apr 30.

16.

Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression.

Beliakova-Bethell N, Jain S, Woelk CH, Witt MD, Sun X, Lada SM, Spina CA, Goicoechea M, Rought SE, Haubrich R, Dubé MP.

Antiviral Res. 2014 Jul;107:42-9. doi: 10.1016/j.antiviral.2014.04.005. Epub 2014 Apr 24.

17.

Differential gene expression in HIV-infected individuals following ART.

Massanella M, Singhania A, Beliakova-Bethell N, Pier R, Lada SM, White CH, Pérez-Santiago J, Blanco J, Richman DD, Little SJ, Woelk CH.

Antiviral Res. 2013 Nov;100(2):420-8. doi: 10.1016/j.antiviral.2013.07.017. Epub 2013 Aug 6.

18.

Highly precise measurement of HIV DNA by droplet digital PCR.

Strain MC, Lada SM, Luong T, Rought SE, Gianella S, Terry VH, Spina CA, Woelk CH, Richman DD.

PLoS One. 2013;8(4):e55943. doi: 10.1371/journal.pone.0055943. Epub 2013 Apr 3.

19.

An iminosugar with potent inhibition of dengue virus infection in vivo.

Perry ST, Buck MD, Plummer EM, Penmasta RA, Batra H, Stavale EJ, Warfield KL, Dwek RA, Butters TD, Alonzi DS, Lada SM, King K, Klose B, Ramstedt U, Shresta S.

Antiviral Res. 2013 Apr;98(1):35-43. doi: 10.1016/j.antiviral.2013.01.004. Epub 2013 Jan 31.

PMID:
23376501
20.

Gamma interferon (IFN-γ) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-α/β receptor-deficient mice.

Prestwood TR, Morar MM, Zellweger RM, Miller R, May MM, Yauch LE, Lada SM, Shresta S.

J Virol. 2012 Dec;86(23):12561-70. doi: 10.1128/JVI.06743-11. Epub 2012 Sep 12.

21.

STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor.

Perry ST, Buck MD, Lada SM, Schindler C, Shresta S.

PLoS Pathog. 2011 Feb;7(2):e1001297. doi: 10.1371/journal.ppat.1001297. Epub 2011 Feb 17.

22.

Cardif-mediated signaling controls the initial innate response to dengue virus in vivo.

Perry ST, Prestwood TR, Lada SM, Benedict CA, Shresta S.

J Virol. 2009 Aug;83(16):8276-81. doi: 10.1128/JVI.00365-09. Epub 2009 Jun 3.

Supplemental Content

Support Center